Rui Zhang1, Jiang Qian, Jie Guo, Yi-Fei Yuan, Kang Xue. 1. Department of Ophthalmology, Eye and ENT Hospital Affiliated to Fudan University, No. 83, Fenyang Road, Shanghai 200031, China. zhangrui946@sohu.com
Abstract
PURPOSE: To determine whether treatment with anti-IL-17 antibody could suppress the intraocular inflammation of experimental autoimmune uveoretinitis (EAU) in rats. METHODS: Rats were immunized with interphotoreceptor retinoid binding protein (IRBP) R16 peptide and were treated with anti-IL-17 antibody. Clinical signs of inflammation and ocular histological sections were observed and graded. Cytokine levels of supernatants of cells from draining lymph nodes were measured by enzyme-linked immunosorbent assay (ELISA). Delayed-type hypersensitivity (DTH) and lymphocyte proliferation assay (LPA) were detected. RESULTS: Treatment of EAU with anti-IL-17 antibody delayed the onset of ocular inflammation and markedly inhibited the development of EAU. Antigen-specific DTH and LPA were suppressed, whereas the level of interferon (IFN)-gamma produced by draining lymph node cells was increased after treatment with anti-IL-17 antibody. There was no significant change of IL-5 level as compared with control rats. CONCLUSIONS: These findings demonstrate that blockade of endogenous IL-17 activity by treatment with anti-IL-17 antibody attenuates EAU in rats. IL-17 rather than IFN-gamma plays a crucial role in the development of EAU, and that antagonism of IL-17 could be useful for the treatment of human intraocular autoimmune diseases.
PURPOSE: To determine whether treatment with anti-IL-17 antibody could suppress the intraocular inflammation of experimental autoimmune uveoretinitis (EAU) in rats. METHODS:Rats were immunized with interphotoreceptor retinoid binding protein (IRBP) R16 peptide and were treated with anti-IL-17 antibody. Clinical signs of inflammation and ocular histological sections were observed and graded. Cytokine levels of supernatants of cells from draining lymph nodes were measured by enzyme-linked immunosorbent assay (ELISA). Delayed-type hypersensitivity (DTH) and lymphocyte proliferation assay (LPA) were detected. RESULTS: Treatment of EAU with anti-IL-17 antibody delayed the onset of ocular inflammation and markedly inhibited the development of EAU. Antigen-specific DTH and LPA were suppressed, whereas the level of interferon (IFN)-gamma produced by draining lymph node cells was increased after treatment with anti-IL-17 antibody. There was no significant change of IL-5 level as compared with control rats. CONCLUSIONS: These findings demonstrate that blockade of endogenous IL-17 activity by treatment with anti-IL-17 antibody attenuates EAU in rats. IL-17 rather than IFN-gamma plays a crucial role in the development of EAU, and that antagonism of IL-17 could be useful for the treatment of humanintraocular autoimmune diseases.
Authors: M H Hu; Q F Zheng; X Z Jia; Y Li; Y C Dong; C Y Wang; Q Y Lin; F Y Zhang; R B Zhao; H W Xu; J H Zhou; H P Yuan; W H Zhang; H Ren Journal: Clin Exp Immunol Date: 2014-02 Impact factor: 4.330
Authors: So Jin Bing; Itay Shemesh; Wai Po Chong; Reiko Horai; Yingyos Jittayasothorn; Phyllis B Silver; Benjamin Sredni; Rachel R Caspi Journal: J Autoimmun Date: 2019-03-08 Impact factor: 7.094
Authors: Zili Zhang; Wenwei Zhong; David Hinrichs; Xiumei Wu; Andrew Weinberg; Mark Hall; Doran Spencer; Keith Wegmann; James T Rosenbaum Journal: Am J Pathol Date: 2010-10-15 Impact factor: 4.307
Authors: Kathryn L Pepple; Lauren Rotkis; Jennifer Van Grol; Leslie Wilson; Angela Sandt; Deborah L Lam; Eric Carlson; Russell N Van Gelder Journal: Invest Ophthalmol Vis Sci Date: 2015-12 Impact factor: 4.799